I
Immix Biopharma, Inc. (IMMX)
NCM – Real Time Price. Currency in USD
10.66
+0.74 (7.46%)
At close: May 12, 2026, 4:00 PM EDT
10.70
+0.04 (0.38%)
After-hours: May 12, 2026, 6:48 PM EDT
Get all premium features to the best stock analysis tool
Find any stock by ticker or company name
NCM – Real Time Price. Currency in USD
10.66
+0.74 (7.46%)
At close: May 12, 2026, 4:00 PM EDT
10.70
+0.04 (0.38%)
After-hours: May 12, 2026, 6:48 PM EDT
Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in the development of chimeric antigen receptor cell therapy in light chain Amyloidosis and immune-mediated diseases in the United States and Australia. The company’ lead product is NXC-201 for relapsed/refractory AL Amyloidos. Immix Biopharma, Inc., was incorporated in 2012 and is headquartered in Los Angeles, California.
| Name | Position |
|---|---|
| Dr. David Marks MBBS, Ph.D. | Chief Medical Officer of Cell Therapy |
| Dr. Graham Ross FFPM, M.D. | Chief Medical Officer & Head of Clinical Development |
| Dr. Ilya Rachman M.B.A., M.D., Ph.D. | Co-Founder, CEO, Chief Scientific Officer & Chairman |
| Dr. Vladimir P. Torchilin D.Sc., MSE, Ph.D. | Scientific Co-Founder |
| Mr. Gabriel Morris B.A. | President, CFO & Director |
| Mr. Mel Davis-Pickett | Head of CMC Technical Development |
| Mr. Michael A. Grabow | Chief Commercial Officer |
| Mr. Sean Senn J.D., M.B.A., M.Sc. | Co-Founder |
| Date | Type | Document |
|---|---|---|
| 2026-05-07 | 10-Q | form10-q.htm |
| 2026-04-06 | DEF 14A | formdef14a.htm |
| 2026-03-30 | 8-K | form8-k.htm |
| 2026-03-27 | 10-K/A | form10-ka.htm |
| 2026-01-16 | CORRESP | filename1.htm |
| 2026-01-09 | S-3 | forms-3.htm |
| 2025-12-08 | 8-K | form8-k.htm |
| 2025-11-26 | CORRESP | filename1.htm |
| 2025-11-26 | 8-K | form8-k.htm |
| 2025-11-07 | 10-Q | form10-q.htm |